Synergy Pharmaceuticals Inc (NASDAQ:SGYP) shares reached a new 52-week low during trading on Friday after the company announced weaker than expected quarterly earnings. The company traded as low as $0.35 and last traded at $0.36, with a volume of 121258 shares changing hands. The stock had previously closed at $0.45.
The biopharmaceutical company reported ($0.14) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.13) by ($0.01). The business had revenue of $11.11 million for the quarter, compared to analyst estimates of $15.65 million.
SGYP has been the subject of a number of research reports. HC Wainwright reissued a “buy” rating and issued a $7.00 price target on shares of Synergy Pharmaceuticals in a research note on Tuesday, August 7th. Zacks Investment Research raised shares of Synergy Pharmaceuticals from a “hold” rating to a “buy” rating and set a $2.00 price objective for the company in a research note on Tuesday, August 14th. BidaskClub cut shares of Synergy Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Wednesday, September 12th. Canaccord Genuity cut shares of Synergy Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, October 26th. Finally, BTIG Research cut shares of Synergy Pharmaceuticals from a “buy” rating to a “neutral” rating in a research note on Friday, October 26th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and one has issued a buy rating to the company. The stock has an average rating of “Hold” and a consensus target price of $8.17.
The stock has a market cap of $110.31 million, a price-to-earnings ratio of -0.36 and a beta of 2.38.
Synergy Pharmaceuticals Company Profile (NASDAQ:SGYP)
Synergy Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat gastrointestinal diseases and disorders. Its lead product is plecanatide, a novel uroguanylin based gastrointestinal platform that is traded under the TRULANCE name for the treatment of chronic idiopathic constipation and irritable bowel syndrome.
Recommended Story: Stock Symbols, CUSIP and Other Stock Identifiers
Receive News & Ratings for Synergy Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synergy Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.